Global Cancer Immunotherapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Monoclonal Antibodies, Immunomodulators & Oncolytic Viral Therapies, and Cancer Vaccines.

By Cancer Type;

Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Ovarian Cancer.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn119494356 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Cancer Immunotherapy Market (USD Million), 2021 - 2031

In the year 2024, the Global Cancer Immunotherapy Market was valued at USD 145,088.87 million. The size of this market is expected to increase to USD 365,286.49 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 14.1%.

The global cancer immunotherapy market has witnessed remarkable growth in recent years, fueled by advancements in medical research, rising cancer prevalence worldwide, and the increasing demand for targeted and personalized treatment options. Immunotherapy, which harnesses the body's immune system to fight cancer cells, has emerged as a promising approach in the battle against various types of cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, immunotherapy offers the potential for fewer side effects and durable responses.

Key drivers propelling the growth of the cancer immunotherapy market include the expanding pipeline of immunotherapeutic agents, regulatory approvals for new indications, and growing investments in research and development by pharmaceutical companies and biotechnology firms. Moreover, the advent of novel immunotherapy modalities, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines, has revolutionized cancer treatment paradigms and expanded the therapeutic options available to patients.

The adoption of cancer immunotherapy is further bolstered by increasing awareness among healthcare professionals and patients about its benefits, along with supportive government initiatives and reimbursement policies. Additionally, collaborations and partnerships between academia, industry players, and research institutions have accelerated the translation of scientific discoveries into clinical applications, driving the expansion of the global cancer immunotherapy market.

Despite the significant progress achieved, challenges persist in realizing the full potential of immunotherapy, including the high cost of treatment, the need for biomarker-driven patient selection, and the occurrence of immune-related adverse events. However, ongoing research efforts aimed at overcoming these challenges, coupled with advancements in technologies such as next-generation sequencing and precision medicine, hold promise for further enhancing the efficacy and accessibility of cancer immunotherapy, thereby shaping the future landscape of cancer care.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Cancer Type
    3. Market Snapshot, By Region
  4. Global Cancer Immunotherapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advancements in Immunotherapy Techniques
        2. Increasing Cancer Incidence
        3. Favorable Regulatory Environment
        4. Growing Investment in Research and Development
      2. Restraints
        1. High Cost of Treatment
        2. Adverse Side Effects
        3. Limited Efficacy in Certain Cancers
        4. Regulatory Challenges
      3. Opportunities
        1. Personalized Immunotherapy
        2. Expansion in Emerging Markets
        3. Combination Therapies
        4. Focus on Early-Stage Cancers
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Cancer Immunotherapy Market, By Product, 2021 - 2031 (USD Million)
      1. Monoclonal Antibodies
      2. Immunomodulators
      3. Oncolytic viral therapies and cancer vaccines
    2. Global Cancer Immunotherapy Market, By Cancer Type, 2021 - 2031 (USD Million)
      1. Lung cancer
      2. Breast cancer
      3. Colorectal cancer
      4. Melanoma
      5. Prostate cancer
      6. Head and neck cancer
      7. Ovarian cancer
    3. Global Cancer Immunotherapy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Bristol Myers Squibb
      2. Merck & Co
      3. Roche Holding AG
      4. AstraZeneca
      5. Novartis AG
      6. Pfizer Inc
      7. Amgen Inc
      8. GlaxoSmithKline plc
      9. Johnson & Johnson
      10. Celgene Corporation
  7. Analyst Views
  8. Future Outlook of the Market